Prophylaxis of Antifungal Drugs against Systemic Fungemia induced by Oral Candidiasis in Mice
Abstract
:1. Introduction
2. Materials and Methods
2.1. Animals
2.2. Experimental Schedule
2.3. Colony Forming Units
2.4. Blood Culture
2.5. Multiplex PCR and Nested PCR
2.6. Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Katagiri, H.; Fukui, K.; Nakamura, K.; Tanaka, A. Systemic hematogenous dissemination of mouse oral candidiasis is induced by oral mucositis. Odontology 2018, 106, 389–397. [Google Scholar] [CrossRef] [PubMed]
- Lyon, S. Antifungal prophylaxis: Why, what and how? Future Microbiol. 2016, 11, 11–15. [Google Scholar] [CrossRef] [PubMed]
- Flowers, C.R.; Seidenfeld, J.; Bow, E.J.; Karten, C.; Gleason, C.; Hawley, D.K.; Kuderer, N.M.; Langston, A.A.; Marr, K.A.; Rolston, K.V.I.; et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2013, 31, 794–810. [Google Scholar] [CrossRef]
- Lu, S.-Y. Oral candidosis: Pathophysiology and best practice for diagnosis, classification, and successful management. J. Fungi 2021, 7, 555. [Google Scholar] [CrossRef] [PubMed]
- Akpan, A. Oral candidiasis. Postgrad. Med. J. 2002, 78, 455–459. [Google Scholar] [CrossRef] [PubMed]
- Kottmann, H.E.; Derman, S.H.; Noack, M.J.; Barbe, A.G. The underestimated problem of oral candida colonization—An observational pilot study in one nursing home. Clin. Exp. Dent. Res. 2019, 5, 683–691. [Google Scholar] [CrossRef]
- Deepa, A.G.; Nair, B.J.; Sivakumar, T.T.; Joseph, A.P. Uncommon opportunistic fungal infections of oral. J. Oral Maxillofac. Pathol. 2014, 18, 235. [Google Scholar] [CrossRef]
- Meena, D.S.; Kumar, D. Candida pneumonia: An innocent bystander or a silent killer? Med. Princ. Pract. 2021, 31, 98–102. [Google Scholar] [CrossRef]
- Takakura, N.; Sato, Y.; Ishibashi, H.; Oshima, H.; Uchida, K.; Yamaguchi, H.; Abe, S. A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush. Microbiol. Immunol. 2003, 47, 321–326. [Google Scholar] [CrossRef]
- Bougnoux, M.-E.; Dupont, C.; Mateo, J.; Saulnier, P.; Faivre, V.; Payen, D.; Nicolas-Chanoine, M.-H. Serum is more suitable than whole blood for diagnosis of systemic candidiasis by nested PCR. J. Clin. Microbiol. 1999, 37, 925–930. [Google Scholar] [CrossRef] [Green Version]
- Majima, T.; Ito-Kuwa, S.; Nagatomi, R.; Nakamura, K. Study of the oral carriage of candida sp. in dental students and staff—Identification of Candida sp. and background survey. Oral Sci. Int. 2013, 11, 30–34. [Google Scholar] [CrossRef]
- Fisher, M.C.; Alastruey-Izquierdo, A.; Berman, J.; Bicanic, T.; Bignell, E.M.; Bowyer, P.; Bromley, M.; Brüggemann, R.; Garber, G.; Cornely, O.A.; et al. Tackling the emerging threat of antifungal resistance to human health. Nat. Rev. Microbiol. 2022, 20, 557–571. [Google Scholar] [CrossRef] [PubMed]
- Kao, W.-Y.; Su, C.-W.; Huang, Y.-S.; Chou, Y.-C.; Chen, Y.-C.; Chung, W.-H.; Hou, M.-C.; Lin, H.-C.; Lee, F.-Y.; Wu, J.-C. Risk of oral antifungal agent-induced liver injury in Taiwanese. Br. J. Clin. Pharmacol. 2013, 77, 180–189. [Google Scholar] [CrossRef] [PubMed]
- Saliba, F. Antifungals and renal safety—Getting the balance right. Int. J. Antimicrob. Agents 2006, 27, 21–24. [Google Scholar] [CrossRef] [PubMed]
- Tragiannidis, A.; Gkampeta, A.; Vousvouki, M.; Vasileiou, E.; Groll, A.H. Antifungal agents and the kidney: Pharmacokinetics, clinical nephrotoxicity, and interactions. Expert Opin. Drug Saf. 2021, 20, 1061–1074. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.C.; Sorrell, T.C. Antifungal agents. Med. J. Aust. 2007, 187, 404–409. [Google Scholar] [CrossRef] [PubMed]
- Teixeira, M.M.; Carvalho, D.T.; Sousa, E.; Pinto, E. New antifungal agents with azole moieties. Pharmaceuticals 2022, 15, 1427. [Google Scholar] [CrossRef]
- Godamudunage, M.P.; Grech, A.M.; Scott, E.E. Comparison of antifungal azole interactions with adult cytochrome P450 3A4 versus neonatal cytochrome P450 3A7. Drug Metab. Dispos. 2018, 46, 1329–1337. [Google Scholar] [CrossRef]
- Zhang, L.-W.; Fu, J.-Y.; Hua, H.; Yan, Z.-M. Efficacy and safety of miconazole for oral candidiasis: A systematic review and meta-analysis. Oral Dis. 2015, 22, 185–195. [Google Scholar] [CrossRef]
- Quindos, G.; Gil-Alonso, S.; Marcos-Arias, C.; Sevillano, E.; Mateo, E.; Jauregizar, N.; Eraso, E. Therapeutic tools for oral candidiasis: Current and new antifungal drugs. Med. Oral Patol. Oral Cir. Bucal 2019, 24, 172–180. [Google Scholar] [CrossRef]
- Isham, N.; Ghannoum, M.A. Antifungal activity of miconazole against recent candida strains. Mycoses 2010, 53, 434–437. [Google Scholar] [CrossRef] [PubMed]
- Martin, M.V. The use of fluconazole and itraconazole in the treatment of candida albicans infections: A Review. J. Antimicrob. Chemother. 2000, 45, 555. [Google Scholar] [CrossRef]
- Pappas, P.G.; Lionakis, M.S.; Arendrup, M.C.; Ostrosky-Zeichner, L.; Kullberg, B.J. Invasive candidiasis. Nat. Rev. Dis. Prim. 2018, 4, 1–20. [Google Scholar] [CrossRef]
- Pappas, P.G.; Kauffman, C.A.; Andes, D.; Benjamin, D.K.; Calandra, T.F.; Edwards, J.E.; Filler, S.G.; Fisher, J.F.; Kullberg, B.-J.; Zeichner, L.O.; et al. Clinical practice guidelines for the management candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48, 503–535. [Google Scholar] [CrossRef] [PubMed]
- Sawant, B.; Khan, T. Recent advances in delivery of antifungal agents for therapeutic management of Candidiasis. Biomed. Pharmacother. 2017, 96, 1478–1490. [Google Scholar] [CrossRef] [PubMed]
- Pappas, P.G.; Kauffman, C.A.; Andes, D.R.; Clancy, C.J.; Marr, K.A.; Ostrosky-Zeichner, L.; Reboli, A.C.; Schuster, M.G.; Vazquez, J.A.; Walsh, T.J.; et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2015, 62, e1–e50. [Google Scholar] [CrossRef] [Green Version]
Group A | Group B | Group C | Negative Control | |
---|---|---|---|---|
Positive animals/Total animals | 4/10 | 2/10 | 1/10 | 0/10 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ninomiya, K.; Katagiri, H.; Hara, H.; Fukui, K.; Haga-Tsujimura, M.; Nakahara, K.; Nakamura, K. Prophylaxis of Antifungal Drugs against Systemic Fungemia induced by Oral Candidiasis in Mice. Curr. Issues Mol. Biol. 2023, 45, 1306-1313. https://doi.org/10.3390/cimb45020085
Ninomiya K, Katagiri H, Hara H, Fukui K, Haga-Tsujimura M, Nakahara K, Nakamura K. Prophylaxis of Antifungal Drugs against Systemic Fungemia induced by Oral Candidiasis in Mice. Current Issues in Molecular Biology. 2023; 45(2):1306-1313. https://doi.org/10.3390/cimb45020085
Chicago/Turabian StyleNinomiya, Kazunori, Hiroki Katagiri, Hajime Hara, Kayoko Fukui, Maiko Haga-Tsujimura, Ken Nakahara, and Kenjirou Nakamura. 2023. "Prophylaxis of Antifungal Drugs against Systemic Fungemia induced by Oral Candidiasis in Mice" Current Issues in Molecular Biology 45, no. 2: 1306-1313. https://doi.org/10.3390/cimb45020085
APA StyleNinomiya, K., Katagiri, H., Hara, H., Fukui, K., Haga-Tsujimura, M., Nakahara, K., & Nakamura, K. (2023). Prophylaxis of Antifungal Drugs against Systemic Fungemia induced by Oral Candidiasis in Mice. Current Issues in Molecular Biology, 45(2), 1306-1313. https://doi.org/10.3390/cimb45020085